A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors

Sponsor
Eli Lilly and Company
Study ID
NCT06235983
Phase
PHASE1
Status
Completed

Conditions

  • Advanced Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an open-label, single-arm, multicenter, Phase 1 study of LY3537982 as monotherapy in Chinese participants with KRAS G12C-mutant advanced solid tumors. The main purpose of this study is to determine how much of LY3537982 gets into the bloodstream and how long it takes the body to eliminate it in Chinese participants. The safety, tolerability and preliminary efficacy of LY3537982 will also be evaluated. Approximately 12 patients will be enrolled in this study.

Key Dates

Start date
Feb 29, 2024
Status verified
May 2026
Primary completion
Jul 2, 2025
Completion
Mar 30, 2026

Study Design

Enrollment
12 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: LY3537982
    LY3537982 administered orally.

Primary Outcome Measure

Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of LY3537982 [ Time Frame: Predose approximately up to 18 weeks ]

Related Studies